Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,578.68
(
-0.02%
)
US TECH 100
29,589.65
(
0.19%
)
Dow Jones
50,797.38
(
-0.46%
)
Brent Oil
96.60
(
5.73%
)
Bitcoin
71,200.09
(
-3.20%
)
News Focus
News Focus
Post# of 108195
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mm2k

Send PM Follow Ignore
Followers 0
Posts 996
Boards Moderated 0
Alias Born 06/20/2017

mm2k

Re: DewDiligence post# 47496

Wednesday, 12/27/2017 11:53:43 AM

Wednesday, December 27, 2017 11:53:43 AM

Post# of 108195
Dew, given all the positive news and preliminary results surrounding neoantigen vaccines, why is there not much excitement about the Advaxis implementation? Is there some perceived disadvantage of their approach, or is the only disadvantage that they have not yet started a phase I trial? Are the companies mentioned in this article further ahead in that sense?

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today